Hecq J.-D.,Yvoir and Drug Stability Research Group |
Lewis A.L.,Biocompatibles UK Ltd |
Vanbeckbergen D.,Scientific Support Unit |
Athanosopoulos A.,Drug Stability Research Group |
And 4 more authors.
Journal of Oncology Pharmacy Practice | Year: 2013
Purpose: Evaluation of doxorubicin stability over time when stored into the DC Bead embolic agent, in various containers, which are used for the delivery of the doxorubicin-loaded beads to the patients for up to 14 days under refrigerated conditions.Methods: The doxorubicin was loaded through the ionic exchange mechanism into the calibrated polyvinyl alcohol-based hydrogel beads (DC Bead), with the loading process carried out either in the original DC Bead glass vials or within a polypropylene plastic syringe. The loaded samples were eluted at given time points and the extracted doxorubicin was analysed by high-performance liquid chromatography for concentration and chromatographic area response purity.Results: The variance on the doxorubicin concentration of the samples stored in the syringes under refrigerated conditions was less than 10% over the 14 days period. The chromatographic purity of doxorubicin eluted from the DC Bead in their primary glass vial packaging was measured at 99.7%. The dissolution test showed that the elution rate and amount recovered from samples stored in vials were statistically similar between Day 0 and Day 14. The chromatographic purity of the doxorubicin loaded into DC Bead in presence of non-ionic contrast medium was >99.0% for 7 days under refrigerated conditions.Conclusions: Doxorubicin-loaded DC Bead® are shown to have adequate physicochemical stability over a period of 14 days when stored in syringes or vials under refrigerated conditions for up to 14 days. The admixtures of doxorubicin-loaded beads with contrast medium are stable for up to 7 days under refrigerated conditions. © The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
Dewulf J.,Medical laboratory |
Galanti L.,Medical laboratory |
Galanti L.,Drug Stability Research Group |
Godet M.,Medical laboratory |
And 7 more authors.
Annales Pharmaceutiques Francaises | Year: 2015
Introduction: The aim of the study was to investigate the long-term stability of acyclovir 5. mg/mL (a generic product versus the brand name) in NaCl 0.9% after storage at 5. ±. 3. °C and to evaluate the influence of initial freezing and microwave thawing on this stability. Methods: Five bags of Acyclovir® Hospira 5mg/mL (A) and five bags of Zovirax® GSK 5mg/mL (B) were prepared under aseptic conditions and stored 3 months at -20°C, then thawed and stored 30 days at 4°C. Five bags of Acyclovir® 5mg/mL (C) and five bags of Zovirax® 5mg/mL (D) were also prepared under aseptic conditions and stored 30 days at 5±3°C. Optic density measurement at different wavelengths, pH measurement and optic microscope observations were performed periodically during the storage. A forced degradation test with HCl 12M and NaOH 5M before and after heating at 100°C was also performed. The concentrations were measured by HPLC-PDA. Results: The only one forced degradation test that yielded chromatograms with degradation products peak was the test with the acid solution heated at 100°C without interference with the native product. No significant change in pH values or optic densities were seen during the study for both products. No crystals were seen with the optic microscope during the study. Acyclovir® and Zovirax® solutions were stable for at least 21 days according to the FDA recommendations. Moreover, there was no statistical difference between regression lines of those two products and two storage conditions. Conclusion: Under the conditions of this study, Acyclovir® 5mg/mL in 100mL of NaCl 0.9% infusion remains stable at least for 21 days at 5±3°C with or without freezing at -20°C during the three previous months. There is no statistical difference between the brand name and a generic product. Acyclovir may be prepared in advanced by a centralized intravenous additive service, frozen in polyolefin bags and microwave thawed before storage under refrigeration until 21 days. © 2014 Elsevier Masson SAS.
Huvelle S.,Medical laboratory |
Godet M.,Medical laboratory |
Godet M.,Drug Stability Research Group |
Hecq J.-D.,CHU Dinant Godinne |
And 6 more authors.
Annales Pharmaceutiques Francaises | Year: 2016
Introduction: Ketamine hydrochloride (Ketalar®) injection is often used as a general anesthetic agent. It is particularly suited to short-term interventions. It can also be used as an inducer of anesthesia before the administration of other anesthetic agents. The aim of this study was to evaluate the stability of ketamine hydrochloride in 3ml polypropylene syringes after storage for up to 180days at room temperature. Method: Syringes containing ketamine hydrochloride (50. mg/ml) were prepared and stored at room temperature (25. °C) for 180. days. The concentrations were measured by validated ultra-performance liquid chromatography-diode array detection at 0, 7, 14, 28, 60, 84, 112, 140 and 180. days. A degradation test was performed to evaluate the specificity of the analysis. At each time point, the pH, color and visible particles of each solution were also assessed. Results: Degradation tests proved no interfering peaks with ketamine. All solutions were physically stable during the storage. The lower confidence limit of the concentration for these solutions remains superior to 90% of the initial concentration at this date as recommended by the Food and Drug Administration (FDA) until 180. days (100%. ±. 2%). Conclusion: Solutions of ketamine (50. mg/ml) were chemically stable for 180. days in polypropylene syringes with storage at room temperature and could be prepared in advance by a centralized intravenous admixture service. © 2016 Académie Nationale de Pharmacie.